Cosentyx® (secukinumab) Intravenous

Intravenous Cosentyx (secukinumab) is covered only for adults (≥18) with FDA‑approved indications — active psoriatic arthritis, active ankylosing spondylitis, or active non‑radiographic axial spondyloarthritis with objective inflammation — and is not covered for pediatric or non‑FDA indications. Coverage requires rheumatologist prescribing/consult (dermatologist acceptable for psoriatic arthritis), weight‑based dosing per label with a 300 mg maximum maintenance infusion, documentation of age/indication (for non‑radiographic axial spondyloarthritis: elevated CRP or sacroiliitis on MRI), reauthorization after ≥6 months on therapy with documented clinical benefit (objective measure or symptom improvement), and approvals are issued for 12 months.

"When requesting Cosentyx (secukinumab) intravenous, the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable saf..."